Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188109 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Chae-Yeon Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Drugs, Chinese Herbal, Dyslipidemias, Obesity. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Obesity, diabetes, and dyslipidemia form an interconnected metabolic disease cluster driven by insulin resistance and chronic inflammation. This study evaluated the clinical efficacy and multi-target mechanisms of Coptidis Rhizoma for these metabolic disorders through an integrated systematic review, meta-analysis of randomized controlled trials (RCTs), network pharmacology, and molecular docking. Meta-analysis of 19 RCTs (n = 1718) demonstrated that Coptidis-containing formulations, primarily as adjunctive therapy, significantly improved primary clinical endpoints across all three metabolic conditions: body mass index (BMI: SMD = −0.72, 95% CI [−1.00, −0.44], p < 0.00001), glycated hemoglobin (HbA1c: SMD = −0.77, 95% CI [−1.07, −0.47], p < 0.00001), and low-density lipoprotein cholesterol (LDL-C: SMD = −1.10, 95% CI [−1.57, −0.62], p < 0.00001). Network analysis revealed shared targets enriched in lipid metabolism, inflammatory signaling, and PI3K-Akt/MAPK cascades. Molecular docking demonstrated favorable structural compatibility and predicted docking scores (ranging from −7.1 to −9.5 kcal/mol) of berberine toward key hub proteins, including PIK3CA, JAK2, MAOA, and PARP1. Consequently, Coptidis Rhizoma provides tangible clinical benefits across interconnected metabolic outcomes via the multi-target regulation of inflammatory and insulin signaling pathways. Clinically, Coptidis-containing formulations show promise as a complementary adjunct to conventional metabolic therapies, though future large-scale, standardized RCTs remain necessary to confirm long-term safety and optimize dosing regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
- Department of Nephrology & Endocrinology, Kyung Hee University Korean Medicine Hospital, Kyung Hee Medical Center, 23, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
ORCID-Profile: Chae-Yeon Kang, Yeon-Joo Yoo, Ji-Han Kim, Min-Seong Lee, Byung-Cheol Lee
Förderung
- Ministry of Health and Welfare
Zitieren
APA
Kang, C. Y., Yoo, Y. J., Kim, J. H., Yoo, S. H., Kim, H. J., Lee, M. S., & Lee, B. C. (2026). Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188109
Vancouver
Kang CY, Yoo YJ, Kim JH, Yoo SH, Kim HJ, Lee MS, et al. Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188109
BibTeX
@article{Kang2026,
author = {Kang, Chae-Yeon and Yoo, Yeon-Joo and Kim, Ji-Han and Yoo, Seung-Hoon and Kim, Hyun-Joo and Lee, Min-Seong and Lee, Byung-Cheol},
title = {Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188109}
}
EUVIMED